Cargando…

Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy

OBJECTIVE: The aim of this study was to evaluate the biochemical recurrence (BCR) in patients with high-risk prostate cancer (PCa) treated with radical prostatectomy (RP) or radiotherapy (RT) plus androgen deprivation therapy (ADT). METHODS: Subjects were patients with National Comprehensive Cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yutaka, Kiba, Keisuke, Yoshikawa, Motokiyo, Hirayama, Akihide, Kunikata, Seiji, Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144907/
https://www.ncbi.nlm.nih.gov/pubmed/27981044
http://dx.doi.org/10.2147/RRU.S120748
_version_ 1782473202607325184
author Yamamoto, Yutaka
Kiba, Keisuke
Yoshikawa, Motokiyo
Hirayama, Akihide
Kunikata, Seiji
Uemura, Hirotsugu
author_facet Yamamoto, Yutaka
Kiba, Keisuke
Yoshikawa, Motokiyo
Hirayama, Akihide
Kunikata, Seiji
Uemura, Hirotsugu
author_sort Yamamoto, Yutaka
collection PubMed
description OBJECTIVE: The aim of this study was to evaluate the biochemical recurrence (BCR) in patients with high-risk prostate cancer (PCa) treated with radical prostatectomy (RP) or radiotherapy (RT) plus androgen deprivation therapy (ADT). METHODS: Subjects were patients with National Comprehensive Cancer Network-defined high-risk PCa treated with either RP or RT plus ADT. We calculated BCR-free survival in patients with those treatments and evaluated risk factor against BCR. RESULTS: A total of 114 patients, 71 RP and 43 RT plus ADT, were evaluated. A total of 59 and 20.9% of patients experienced BCR in the RP and RT treatment groups, respectively. The 5-year BCR-free survival probabilities improved significantly for patients who received RT compared to those who received RP (81.3 vs 37.3%, P<0.001). According to the number of risk factors, 59.2% of patients in the RP and 51.2% of patients in the RT treatment groups were classified with one risk factor (P<0.014). The 5-year BCR-free survival probabilities for patients treated with RP were 46.6 and 21.7% for one and multiple risk factors, respectively (P=0.008). On univariate analysis, only the number of risk factors had a significant impact on the risk of BCR. Meanwhile, there were no significant differences in the 5-year BCR-free survival probabilities between one and multiple risk factors in patients treated with RT. CONCLUSION: Among patients treated with RP, a marked heterogeneity existed in the oncological outcomes. Based on these findings, the number of risk factors should be emphasized to decide the optimal treatments for patients with high-risk PCa.
format Online
Article
Text
id pubmed-5144907
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-51449072016-12-15 Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy Yamamoto, Yutaka Kiba, Keisuke Yoshikawa, Motokiyo Hirayama, Akihide Kunikata, Seiji Uemura, Hirotsugu Res Rep Urol Original Research OBJECTIVE: The aim of this study was to evaluate the biochemical recurrence (BCR) in patients with high-risk prostate cancer (PCa) treated with radical prostatectomy (RP) or radiotherapy (RT) plus androgen deprivation therapy (ADT). METHODS: Subjects were patients with National Comprehensive Cancer Network-defined high-risk PCa treated with either RP or RT plus ADT. We calculated BCR-free survival in patients with those treatments and evaluated risk factor against BCR. RESULTS: A total of 114 patients, 71 RP and 43 RT plus ADT, were evaluated. A total of 59 and 20.9% of patients experienced BCR in the RP and RT treatment groups, respectively. The 5-year BCR-free survival probabilities improved significantly for patients who received RT compared to those who received RP (81.3 vs 37.3%, P<0.001). According to the number of risk factors, 59.2% of patients in the RP and 51.2% of patients in the RT treatment groups were classified with one risk factor (P<0.014). The 5-year BCR-free survival probabilities for patients treated with RP were 46.6 and 21.7% for one and multiple risk factors, respectively (P=0.008). On univariate analysis, only the number of risk factors had a significant impact on the risk of BCR. Meanwhile, there were no significant differences in the 5-year BCR-free survival probabilities between one and multiple risk factors in patients treated with RT. CONCLUSION: Among patients treated with RP, a marked heterogeneity existed in the oncological outcomes. Based on these findings, the number of risk factors should be emphasized to decide the optimal treatments for patients with high-risk PCa. Dove Medical Press 2016-12-02 /pmc/articles/PMC5144907/ /pubmed/27981044 http://dx.doi.org/10.2147/RRU.S120748 Text en © 2016 Yamamoto et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yamamoto, Yutaka
Kiba, Keisuke
Yoshikawa, Motokiyo
Hirayama, Akihide
Kunikata, Seiji
Uemura, Hirotsugu
Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
title Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
title_full Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
title_fullStr Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
title_full_unstemmed Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
title_short Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
title_sort evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144907/
https://www.ncbi.nlm.nih.gov/pubmed/27981044
http://dx.doi.org/10.2147/RRU.S120748
work_keys_str_mv AT yamamotoyutaka evaluationofbiochemicalrecurrenceinpatientswithhighriskprostatecancertreatedwithradicalprostatectomyandradiotherapyplusandrogendeprivationtherapy
AT kibakeisuke evaluationofbiochemicalrecurrenceinpatientswithhighriskprostatecancertreatedwithradicalprostatectomyandradiotherapyplusandrogendeprivationtherapy
AT yoshikawamotokiyo evaluationofbiochemicalrecurrenceinpatientswithhighriskprostatecancertreatedwithradicalprostatectomyandradiotherapyplusandrogendeprivationtherapy
AT hirayamaakihide evaluationofbiochemicalrecurrenceinpatientswithhighriskprostatecancertreatedwithradicalprostatectomyandradiotherapyplusandrogendeprivationtherapy
AT kunikataseiji evaluationofbiochemicalrecurrenceinpatientswithhighriskprostatecancertreatedwithradicalprostatectomyandradiotherapyplusandrogendeprivationtherapy
AT uemurahirotsugu evaluationofbiochemicalrecurrenceinpatientswithhighriskprostatecancertreatedwithradicalprostatectomyandradiotherapyplusandrogendeprivationtherapy